217  0 Kommentare Philips presents study results at Heart Rhythm Annual Meeting demonstrating benefits of its AI-powered cardiac monitoring solutions

With cardiovascular disease on the rise, clinicians and health systems continue to look for ways to deliver high-quality care that is both timely and cost-effective. Findings from the three studies highlight the central role mobile cardiac monitoring technology plays in supporting early detection of adverse cardiac events and enabling potentially life-saving interventions for patients, while helping to reduce readmissions and lower costs.

Recently published in The Journal of Comparative Effectiveness Research, a Philips study compares the clinical and economic outcomes of using the Philips mobile cardiac outpatient telemetry (MCOT) wearable ECG sensor with implantable loop recorders (ILRs) in stroke patients to determine how cardiac remote monitoring technology impacts current standards of care. This study analyzed the eighteen months following a stroke event and found that when MCOT was used instead of ILR for post-discharge monitoring:

• Patients experienced significantly lower readmissions (30.2% in the MCOT-monitored group compared to 35.4% in the ILR group);
• Average cost over an 18-month period following the stroke event was reduced by USD 27,429;
• Emergency department utilization was significantly lower;
• Patients with complications and comorbidities from the index stroke experienced a higher rate of survival.

Lesen Sie auch

339 Milliarden US-Dollar

Dividendenwachstum auf Rekordkurs: Premiere für Meta und Alibaba

31.05.24, 06:02

Wasserstoff-Ausblick

Nel und Plug Power: Wann erlebt der Wasserstoff-Markt seinen Durchbruch?

29.05.24, 16:30

Ihre wichtigsten Termine

Heute im Fokus: Meta, Volkswagen AG, HP, Douglas, Salesforce und Aroundtown

29.05.24, 04:30

iPhone-Absatz explodiert

Apple feiert glänzendes Comeback auf hart umkämpftem chinesischen Markt

28.05.24, 13:04

Manish Wadhwa, Chief Medical Officer for Philips Ambulatory Monitoring & Diagnostics, said: “As we explore how specific ambulatory monitoring devices, like MCOT, impact clinical outcomes, data demonstrates that choice of monitoring modality does affect the cost-effectiveness of care and patient outcomes. Effective cardiac monitoring starts with quality data, and with the AI-powered data platform behind MCOT, Philips is uniquely positioned to help care teams make quick, impactful, and cost-conscious decisions for their cardiac patients.”

Diskutieren Sie über die enthaltenen Werte

Koninklijke Philips

Aktie

Beiträge: 109